Application of KRT15 in auxiliary diagnosis and targeted therapy of esophageal cancer

Through detection and targeting KRT15, ​​the problem of lack of effective methods in the diagnosis and treatment of esophageal cancer is solved, and the accurate diagnosis and effective treatment of esophageal cancer is achieved, which significantly affects the survival time and treatment effect of patients.

CN114672553BActive Publication Date: 2024-11-01CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202011546940.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-12-24
Publication Date
2024-11-01
Estimated Expiration
2040-12-24

AI Technical Summary

Technical Problem

There is a lack of effective methods in the prior art to assist in the diagnosis and treatment of esophageal cancer, especially the mechanism and application of KRT15 in esophageal cancer have not been clarified.

Method used

Detection agents for detecting KRT15 expression levels are developed to assist in the diagnosis and prognosis judgment of esophageal cancer, and to inhibit its expression or function through reagents targeting KRT15 to inhibit the proliferation of esophageal cancer cells and tumor growth.

Benefits of technology

By detecting the expression level of KRT15, ​​the degree of differentiation, lymph node metastasis risk and prognostic survival time of esophageal cancer can be effectively judged, and the proliferation of esophageal cancer cells and tumor growth can be significantly inhibited through targeted treatment, thereby improving the treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002856641660000041
    Figure BDA0002856641660000041
  • Figure BDA0002856641660000042
    Figure BDA0002856641660000042
  • Figure BDA0002856641660000081
    Figure BDA0002856641660000081
Patent Text Reader

Abstract

The present invention relates to the use of KRT15 in auxiliary diagnosis and targeted therapy of esophageal cancer. Specifically, the present invention relates to the use of a detection agent for detecting the expression level of KRT15 from a subject sample in the preparation of a reagent for auxiliary diagnosis and / or prognosis of esophageal cancer; on the other hand, the present invention relates to the use of a reagent targeting KRT15 in the preparation of a drug for treating esophageal cancer, wherein the reagent targeting KRT15 is a reagent that inhibits and / or reduces the expression level of the KRT15 gene and / or protein, or antagonizes the function of the KRT15 protein.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of diagnosis and treatment of esophageal cancer. Specifically, the present invention relates to the use of KRT15 in auxiliary diagnosis and targeted treatment of esophageal cancer. Background Art

[0002] KRT15 (Keratin 15, CK15 / K15) belongs to the keratin family and is an intermediate filament protein responsible for maintaining the structural integrity of epithelial cells (Omary et al., 2004). A variety of keratins have been discovered, which can be divided into type I keratins and type II keratins according to their isoelectric points and sequences: type I keratins are acidic proteins with a molecular weight of 40-55KDa, including K9-K28 and K31-K40; type II keratins are neutral or alkaline proteins with a molecular weight of 56-70KDa, including K1-K8 and K71-K86. Usually, the two types of keratins are expressed in pairs, and the two are specifically non-covalently bound to form heteropolymers, namely type I / II complexes, which aggregate together to form a characteristic 10nm wide filamentous arrangement (Schweizer et al., 2006). Specific types of keratin are expressed in epithelial cells of different organs. Abnormal expression of keratin is closely related to the occurrence of tumors and is suitable for the diagnosis, classification and prognosis of cancer. For example, K5 / K14 and K1 / K10 are present in basal cells and keratinocytes, respectively. The keratin combination formed by type II K7 or K8 and type I K18 / K19 / K20 / K23 is expressed in the monolayer cells of the epithelial tissue of the digestive organs. K8 and K18 are the only keratins in adult hepatocytes, while the keratin expression types in bile duct cells are K7 / K19 and K8 / K18 (Omary et al., 2009).

[0003] KRT15 is specifically expressed in the basal cell layer of epithelial tissue. What is special is that there is no clear type II keratin that is expressed in conjunction with KRT15 (Waseem et al., 1999). According to the latest information from the UniPort International Protein Database, among the tissues of various human organs, KRT15 is most highly expressed in the esophageal mucosa. Several studies have shown that KRT15-positive cells may have stem cell-like properties, helping cells maintain their self-renewal ability and promoting epithelial cell regeneration: Yang et al. successfully transformed human induced pluripotent stem cells (iPSCs) into an epithelial stem cell (EpSCs) in vitro. This regenerative cell contains a KRT15-positive stem cell population (Yang et al., 2014); Giroux et al. used in vivo genetic lineage tracing technology to discover a long-lived progenitor cell population with stem cell characteristics in the mouse esophagus. This group of cells characteristically expressed KRT15, ​​and the KRT15-negative basal cell population and the positive cell population had significant differences in expression profiles. The absence of KRT15 caused atrophy of the esophageal epithelium (Giroux et al., 2017); they also used mouse models and 3D organ culture technology to study the effect of KRT15 in the small intestine on radiosensitivity and found that KRT15-positive cells in the small intestinal crypts were very tolerant to high doses of radiation, which helped cells repair radiation-induced epithelial damage (Giroux et al., 2018). The expression of KRT15 is closely related to the degree of cell differentiation, and its downregulation is very important for maintaining the keratinization state of cells (Waseem et al., 1999). Therefore, KRT15 is highly expressed in some tumors derived from epithelial stem cells, such as hair follicle stem cell-derived trichoepithelioma (Jih et al., 1999), lung squamous cell carcinoma (Gomez-Morales et al., 2013; Sanchez-Palencia et al., 2011), breast cancer (Chong et al., 2012), urothelial carcinoma (Tai et al., 2013), etc.In addition, the expression of KRT15 can also be used to divide tumors into multiple subtypes: KRT15 is specifically expressed in the membrane cytoplasm in lung squamous cell carcinoma, which can be distinguished from lung adenocarcinoma (Gomez-Morales et al., 2013; Sanchez-Palencia et al., 2011); Folgueira et al. studied the gene expression profiles of stage II and stage III breast cancer and found that compared with normal tissues, there was a significant difference in the expression of KRT15 in stage II and stage III breast cancer patients (Folgueira et al., 2006); KRT15 combined with TCN1 and HOXB13 can help distinguish borderline and malignant breast cancers and improve the accuracy of breast cancer diagnosis (Chong et al., 2012); other researchers have used different differentiation-related molecules to divide ameloblastoma into multiple subtypes. They proposed that KRT15-positive basal cells in cancer nests are similar to oral epithelial or dentate cells, and KRT15-negative basal cells are similar to outer enamel epithelial cells (Pal et al., 2013). The prognosis of adenoid cystic carcinoma (ACC) is mainly related to the location of the primary tumor. Tumors originating from the skin have a better prognosis, but those originating from the lacrimal gland and salivary gland have a poorer prognosis. Studies have shown that there is a significant difference in the expression of KRT15 in ACCs originating from the skin and salivary glands, which can be used to determine the source of the tumor and then determine the patient's prognosis (North et al., 2015). CD133. + Cells may be involved in the occurrence of liver cancer. Zekri et al. analyzed such cells in liver cancer patients and normal people and found that KRT15 was the only one that was expressed in CD133 in liver cancer patients. + KRT15 is a highly expressed gene in esophageal cancer cells (Zekri et al., 2017). It can be seen that KRT15 is closely related to the occurrence of epithelial tumors and has a good application prospect in clinical diagnosis, prognosis and tumor classification. There is currently no literature reporting the mechanism of action of KRT15 in esophageal cancer cells. Summary of the invention

[0004] The inventors unexpectedly found that the expression of KRT15 varies greatly among different esophageal cancer patients, and KRT15 expression is significantly correlated with lymph node metastasis and differentiation degree, and significantly affects the patient's overall survival time; on the other hand, knocking down the expression of KRT15 can significantly inhibit the proliferation of esophageal cancer cells and inhibit or reduce the tumor growth of esophageal cancer in mice.

[0005] Based on the above unexpected findings, the present invention provides, in a first aspect, use of a detection agent for detecting the expression level of KRT15 in the preparation of a reagent for auxiliary diagnosis and / or prognosis of esophageal cancer.

[0006] In a preferred embodiment, the KRT15 expression level of the present invention refers to the KRT15 gene expression level, including but not limited to the KRT15 mRNA expression level, and / or the KRT15 protein expression level.

[0007] In a preferred embodiment of the present invention, a KRT15 expression level detection agent can be used to determine the KRT15 expression level in a sample of an esophageal cancer patient; by comparing with the KRT15 expression level in a reference sample, the degree of tumor differentiation, the risk of lymph node metastasis and / or the prognosis survival time of the esophageal cancer patient can be determined.

[0008] In another aspect, the present invention provides a use of a detection agent for detecting KRT15 expression level in preparing a reagent for evaluating the therapeutic effect of esophageal cancer patients. Compared with the KRT15 expression level in the patient sample before treatment, a decrease in KRT15 expression level indicates that the treatment is effective.

[0009] In a preferred embodiment of the present invention, the detection agent for detecting the expression level of the KRT15 gene includes but is not limited to primers and / or probes that specifically bind to the KRT15 gene.

[0010] The expression level of the KRT15 gene can be detected by any method known to those skilled in the art, including but not limited to Northern blot, polymerase chain reaction, reverse transcriptase PCR, quantitative real-time PCR, nanoarray, microarray, autoradiography or in situ hybridization.

[0011] In particular, real-time quantitative RT-PCR (qRT-PCR) can be used. In some embodiments, qRT-PCR can be used to detect and quantify KRT15 mRNA. qRT-PCR is a well-known and readily available technique for those skilled in the art and does not require detailed description. For example, commercially available qRT-PCR-based methods (such as Array), primers and / or probes can be easily designed based on the sequence of KRT15 known in the art.

[0012] In a preferred embodiment of the present invention, the detection agent for detecting the expression level of KRT15 protein includes but is not limited to an antibody that specifically binds to KRT15 protein.

[0013] The expression level of KRT15 protein can be detected by any method known to those skilled in the art, including but not limited to Western blot, immunoblotting, ELISA, and mass spectrometry.

[0014] In another aspect, the present invention provides use of an agent targeting KRT15 in the preparation of a medicament for treating esophageal cancer, wherein the agent targeting KRT15 inhibits and / or reduces the expression level of the KRT15 gene and / or protein, or antagonizes the function of the KRT15 protein.

[0015] In a preferred embodiment of the present invention, the agent for inhibiting and / or reducing the expression level of the KRT15 gene is a nucleic acid.

[0016] In a more specific embodiment, the agent for inhibiting and / or reducing the expression level of KRT15 gene is an antisense nucleic acid molecule complementary to the KRT15 gene sequence, preferably a single-stranded RNA molecule reverse complementary to the KRT15 gene, which can specifically bind to and inhibit the endogenous KRT15 gene.

[0017] In a preferred embodiment of the present invention, suppressing and / or reducing the expression level of KRT15 protein is by knocking down the expression level of KRT15 protein with interfering RNA. When introduced in vivo, interfering RNA forms RNA-induced silencing complex ("RISC") with other proteins and starts a process called RNA interference (RNAi). In the RNAi process, RISC merges a chain of single-stranded interfering RNA or double-stranded interfering RNA. The chain incorporated serves as a template for RISC to recognize complementary mRNA transcripts. Once complementary mRNA is determined, the protein components in RISC activate and cut mRNA, resulting in knocking down of target gene expression. Non-limiting examples of interfering RNA molecules for knocking down target gene expression include siRNA, short hairpin RNA (shRNA), single-stranded interfering RNA and microRNA (miRNA). The method using these interfering RNAs is well known to those skilled in the art.

[0018] In a specific embodiment of the present invention, the function of KRT15 protein is antagonized by using an antagonist of KRT15 protein for treating esophageal cancer. The antagonist of KRT15 protein is an antagonist antibody that specifically binds to and blocks the function of KRT15 protein.

[0019] In another aspect, the present invention provides a method for treating esophageal cancer in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of an agent that inhibits and / or reduces the expression level of KRT15 gene and / or protein, or antagonizes the function of KRT15 protein.

[0020] In another aspect, the present invention provides a method for in vitro screening of anti-esophageal cancer agents, the method comprising the following steps:

[0021] 1) Cultivate esophageal cancer cell lines in vitro;

[0022] 2) contacting the test agent with the esophageal cancer cells cultured in 1), and

[0023] 3) Detecting the expression level of KRT15 gene and / or protein in esophageal cancer cell lines,

[0024] If the expression level of the KRT15 gene and / or protein is significantly reduced compared to before contact with the agent to be tested, the agent to be tested can be used to treat esophageal cancer.

[0025] In a further preferred embodiment, the esophageal cancer cells in the method for in vitro screening of anti-esophageal cancer agents according to the present invention are selected from KYSE150, KSE450 and KYSE510; preferably, the agent to be detected is selected from interfering RNA and antagonistic antibodies that inhibit and / or reduce the expression level of KRT15 gene and / or protein, or antagonize the function of KRT15 protein. Those skilled in the art can select these interfering RNA and antagonistic antibodies according to common knowledge in the art.

[0026] the term

[0027] Unless otherwise specified herein, the terms used herein have the meanings commonly understood by one of ordinary skill in the art.

[0028] As used herein, the gene CDS sequence of KRT15 includes, but is not limited to, the sequence shown in NM_002275.4:

[0029]

[0030] The amino acid sequence of the KRT15 protein is, for example, as shown in NP_002266.3:

[0031]

[0032]

[0033] "Sample" as described herein can be any biological sample derived from an esophageal cancer patient, comprising nucleic acid and / protein. Examples of such samples include liquids (including blood, plasma, serum, urine, semen), tissues, cell samples, organs, biopsy samples, tumor samples, etc. Preferably, the sample is a biopsy sample of a tissue or cell, and more preferably, the sample is a biopsy of an esophageal cancer tissue sample. The sample can be collected according to conventional techniques and directly used for diagnosis or storage. The tumor sample can be fresh, frozen or paraffin-embedded. Typically, available tumor samples are frozen or paraffin-embedded, and most of the time are paraffin-embedded.

[0034] As described herein, the "reference sample" may be a sample derived from a control, the control being a healthy subject or being a patient with esophageal cancer known to have or not have lymph node metastasis, the reference sample including, but not limited to, liquid (including blood, plasma, serum, urine, semen), tissue, cell sample, organ, biopsy sample, tumor sample, etc. Preferably, the sample is a biopsy sample of a tissue or cell, more preferably, the sample is a biopsy of an esophageal cancer tissue sample. Preferably, the reference sample pool comprises samples derived from at least one (preferably several, more preferably at least 5, more preferably at least 6, at least 7, at least 8, at least 9, at least 10) control.

[0035] The term "primer" as used herein refers to a short polynucleotide, typically having a free 3' OH group, that hybridizes to a template and is used to initiate polymerization of a polynucleotide complementary to a target.

[0036] The term "probe" as used herein refers to a short polynucleotide used to detect a polynucleotide sequence complementary to the probe in a hybridization-based assay. The probe may consist of a "fragment" of a polynucleotide as defined herein.

[0037] The term "antibody" as used herein is used in the broadest sense and refers to any immunoglobulin (Ig) molecule comprising two heavy chains and two light chains, as well as any fragment, mutant, variant or derivative thereof, so long as the fragment, mutant, variant or derivative exhibits the desired biological activity (e.g., epitope binding activity).

[0038] As used herein, "inhibiting" and / or "reducing" the expression level of KRT15 refers to a reduction in the expression level of KRT15 by at least 10%, such as at least about 10%, or at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to and including a 100% reduction (i.e., a level that is not present compared to a reference sample), or any reduction between 10-100% compared to a reference level; preferably, the reference level may refer to the level before treatment with the agent of the present invention.

[0039] The terms "treat" or "treatment" include treating a disease or condition described herein in a subject, such as a human, and include: (i) inhibiting the disease or condition, i.e., preventing its occurrence; (ii) relieving the disease or condition, i.e., causing regression of the condition; (iii) slowing the progression of the disease; and / or (iv) inhibiting, relieving or slowing the progression of one or more symptoms of the disease or condition.

[0040] As used herein, the term "knock down" refers to a measurable reduction in the expression of a target mRNA or corresponding protein in a genetically modified cell compared to the expression of the target mRNA or corresponding protein in a corresponding control cell that does not contain a genetic modification that reduces expression. Those skilled in the art will readily understand how to use various genetic methods, such as siRNA, shRNA, miRNA, antisense RNA or other RNA-mediated inhibition techniques, to knock down a target polynucleotide sequence or portion thereof based on the details described herein.

[0041] The term "interfering RNA" refers to an RNA nucleic acid molecule that is double-stranded or single-stranded and is capable of inducing an RNA interference mechanism for knocking down target gene expression.

[0042] As used herein, "siRNA" is a double-stranded RNA, which is generally less than 30 nucleotides in length. Gene silencing by siRNA begins with the incorporation of one strand of the siRNA into a ribonucleoprotein complex called RNA-induced silencing complex (RISC). The strand incorporated into RISC recognizes mRNA molecules that are at least partially complementary to the incorporated siRNA strand, and then RISC cuts these target mRNAs or inhibits their translation.

[0043] The term "miRNA" is a small non-coding RNA molecule that can hybridize to complementary sequences within mRNA molecules, thereby causing cleavage of the mRNA, or destabilizing the mRNA by shortening its poly(A) tail.

[0044] The term "single-stranded interfering RNA" can achieve mRNA silencing in a similar manner to double-stranded siRNA, although less efficiently than double-stranded siRNA. Single-stranded interfering RNA generally has a length of about 19 to about 49 nucleotides.

[0045] The term "short hairpin RNA or small hairpin RNA (shRNA)" is an artificial RNA molecule with a tight hairpin turn that can be used to silence target gene expression through the siRNA produced by it in cells. The expression of shRNA in cells is usually achieved through a plasmid vector or through a viral or bacterial vector. Suitable vectors include, but are not limited to, adeno-associated viruses (AAV), adenoviruses, and lentiviruses. shRNA is a favorable medium for siRNA because it has a relatively low degradation and turnover rate.

[0046] The term "antagonist antibody" is used in the broadest sense and includes antibodies that inhibit or reduce the biological activity of the antigen (e.g., KRT15) to which the antibody binds. Thus, KRT15 antagonist antibodies encompass antibodies that bind to KRT15 and block, inhibit, counteract, antagonize, reduce KRT15 agonist activity to any meaningful extent (including significantly).

[0047] The terms "patient", "subject", "individual" and the like are used interchangeably herein and refer to any animal or its cells suitable for the methods described herein, whether in vitro or in situ. In certain non-limiting embodiments, the patient, subject or individual is a human.

[0048] The terms "treat" or "treatment" include treating a disease or condition described herein in a subject, such as a human, and include: (i) inhibiting the disease or condition, i.e., preventing its occurrence; (ii) relieving the disease or condition, i.e., causing regression of the condition; (iii) slowing the progression of the disease; and / or (iv) inhibiting, relieving or slowing the progression of one or more symptoms of the disease or condition.

[0049] The term "administering" or "giving" a therapeutic agent, such as an agent that reduces KRT15 expression, includes any route of introducing or delivering the therapeutic agent to perform its intended function. Administration can be by any route suitable for delivering an agent. Thus, the delivery route can include intravenous, intramuscular, intraperitoneal, or subcutaneous delivery. In some embodiments, the agent that reduces KRT15 expression is administered directly to the tumor, for example, by injection into the tumor.

[0050] The embodiments of the present invention will be further described below in conjunction with the accompanying drawings and specific examples. However, it should not be understood that the scope of the present invention is limited to these specific examples. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 . Representative images of RNA in situ hybridization (RISH) results of KRT15 in esophageal cancer tissues.

[0052] Figure 2 .Correlation analysis results between KRT15 expression and clinical pathological parameters of esophageal cancer patients. The values ​​below the figure represent the significant difference P value between the two groups. G1: well differentiated, G2: moderately differentiated, G3: poorly differentiated; N0: no lymph node metastasis; N1: lymph node metastasis.

[0053] Figure 3 .Kaplan-Meier survival analysis of KRT15 RNA expression and overall survival in patients undergoing radical resection of esophageal cancer.

[0054] Figure 4 . Representative images of immunohistochemistry results of KRT15 in esophageal cancer tissues.

[0055] Figure 5.Knockdown of KRT15 significantly inhibited the proliferation of esophageal cancer cells. Left: After transient transfection of two siRNAs specific for KRT15 in KYSE150, KYSE450, and KYSE510 cells, 1000 cells / well were inoculated in 96-well plates, and cell viability was detected by CCK-8 method, and the growth curve of 0-5 days was drawn. Error bar represents mean±SD (n=3, ***P<0.001). Right: Western blot detection of the knockdown effect of KRT15 after transfection of siRNA.

[0056] FIG. 6A to FIG. 6B .Knockdown of KRT15 promotes G2 / M arrest in esophageal cancer cells. KRT15-specific siRNA was transfected into KYSE150 and KYSE510 cells, respectively. Cells were collected 48 hours later and the cell cycle distribution was analyzed by flow cytometry after PI staining. The peak graph of the cycle distribution is on the left, and the bar chart is on the right.

[0057] Figure 7 .Knockdown of KRT15 significantly inhibited the subcutaneous tumorigenesis of esophageal cancer cells in nude mice. KYSE150 cells stably expressing non-silencing-shRNA and KRT15-shRNA were subcutaneously inoculated in the right armpit of nude mice. After 21 days of feeding, the nude mice were killed by cervical dislocation. Tumor tissues were dissected, photographed and weighed, and the growth curve of tumor volume and the scatter plot of tumor weight were drawn. Errorbar represents mean±SD (n=6, ***P<0.001).

[0058] Figure 8 .Human receptor tyrosine kinase (RTK) phosphorylation antibody chip detection results. KRT15-specific siRNA was transfected into KYSE150 and KYSE510 cells, respectively. After 48 hours, the cells were collected and proteins were extracted. The changes in the phosphorylation levels of 71 receptor tyrosine kinases were detected using the AAH-PRTK-1 kit. A, the arrangement of the phosphorylation antibody array, the two side-by-side points are the repeats of each antibody. B, the original image of the AAH-PRTK-1 chip detection results, POS1 / 2 and NEG are internal references.

[0059] Fig. 9 . Changes in downstream molecules after knockdown of KRT15. KRT15-specific siRNA was transfected into KYSE150 and KYSE510 cells, respectively. Cells were collected and proteins were extracted 48 hours later. The expression of p-EphA3, EphA3, p-EGFR, EGFR, p-AKT, AKT, as well as p-ERK, ERK was detected by Western blot, with GAPDH as the internal reference.

[0060] Fig.10.SDS-PAGE combined with Coomassie Brilliant Blue staining results.

[0061] Fig.11 .KRT15 interacting protein gene enrichment analysis results.

[0062] Fig.12 .KRT15 interacts with EGFR in esophageal cancer cells. DETAILED DESCRIPTION

[0063] Example 1 Expression of KRT15 in esophageal cancer tissues of patients

[0064] We used RNA in situ hybridization to analyze the expression of KRT15 in esophageal cancer tissues and its relationship with patient prognosis. We selected 1013 tissue samples from esophageal cancer surgery (without any treatment before surgery) collected from Linzhou Esophageal Cancer Hospital in Henan Province from 2011 to 2015 for RNA in situ hybridization analysis. For specific steps, please refer to the Materials and Methods section below.

[0065] The results showed that KRT15 expression varied greatly among different esophageal cancer patients. It was highly expressed in 43.93% (445 / 1013) of esophageal cancer tissues (the mean score of intensity × area was above 3 points), and was not expressed in 38.60% (391 / 1013) of esophageal cancer tissues (the mean score of intensity × area was 0 points). Figure 1 ). The results of correlation analysis of clinical pathological parameters showed that KRT15 expression was correlated with lymph node metastasis and differentiation degree in patients with esophageal cancer ( Figure 2 Kaplan-Meier survival analysis showed that the overall survival time of cases with positive expression of KRT15 was significantly shorter (P=0.0044, Figure 3 ).

[0066] We further used immunohistochemistry to detect the expression of KRT15 in esophageal cancer and its surgical margin tissues ( Figure 4 ), for specific steps, see the Materials and Methods section below. Correlation analysis results showed that the expression of KRT15 at the protein level was significantly correlated with the RNA level (see Table 1 below).

[0067] Table 1. Correlation analysis of KRT15 RNA and protein expression

[0068]

[0069] Example 2 Effect of KRT15 on the proliferation ability of esophageal cancer cells

[0070] In order to explore the mechanism by which KRT15 promotes the development of esophageal cancer, we detected the effect of KRT15 on the malignant phenotype of esophageal cancer cells. Two siRNAs specific for KRT15 were transiently transfected into the esophageal cancer cell lines KYSE150, KYSE450, and KYSE510, which highly expressed KRT15, ​​respectively. The controls included the parental group or the transfection non-silencing group. When the cells were fully attached to the wall, the CCK-8 method was used to detect cell viability. The results showed that after knocking down KRT15, ​​the proliferation ability of esophageal cancer cells was significantly reduced compared with the control group ( Figure 5 ).

[0071] Example 3 Effect of KRT15 on the cell cycle distribution of esophageal cancer cells

[0072] Flow cytometry was used to analyze the proportion of cells in the G0 / G1, G2, and S phases of the cell cycle. The results showed that knockdown of KRT15 promoted G2 / M phase arrest in esophageal cancer cells ( FIG. 6A to FIG. 6B ).

[0073] Example 4 Effect of KRT15 on the Tumor-forming Ability of Esophageal Cancer Cells in Nude Mice

[0074] The constructed pLKO.1-KRT15-shRNA and pLKO.1-non-silencing shRNA vectors were packaged into lentiviral vectors, and the KYSE150 cell lines that stably expressed non-silencing shRNA and KRT15-shRNA were further screened by lentiviral infection. The results of the nude mouse subcutaneous transplant tumor formation experiment showed that compared with the control group, the subcutaneous tumor growth rate in the KRT15-shRNA group was significantly slower and the subcutaneous tumor weight was lighter, with significant differences (P<0.001)( Figure 7 ).

[0075] Example 5 Study on the mechanism of action of KRT15 in esophageal cancer

[0076] KRT15 was transiently knocked down in KYSE150 and KYSE450 esophageal cancer cells. After 48 hours of culture, the cell pellets were collected and proteins were extracted. The AAH-PRTK-1 kit of Raybiotech was used to detect the changes in the phosphorylation levels of 71 receptor tyrosine kinases after changing the expression of KRT15. The raw data obtained by chip scanning was background removed and normalized between chips using Raybiotech software to obtain Normalization 1without background data that can be used for analysis. The differentially expressed proteins were analyzed by fold change (the average fluorescence signal value of each group was >150, and the change was ≤0.83 or ≥1.2). The results showed that after knocking down KRT15, ​​the phosphorylation levels of ACK1, Btk, ALK, and EphA3 in KYSE150 cells were reduced, and the phosphorylation levels of RET, MATK, EGFR, JAK1, PYK2, EphA5, TNK1, HGFR, FER, Fyn, FGFR2, Hck, Dtk, M-CSFR, JAK2, EphB4, and EphA6 were increased; after knocking down KRT15, ​​the phosphorylation levels of LCK, NGFR, ALK, ROR2, JAK2, Btk, EphA3, and IGF-I in KYSE450 cells were increased. The phosphorylation levels of R, EphA1, RET, EphB1, ErbB3, and Axl were decreased, and the phosphorylation levels of EphA6, Dtk, EphB3, FER, FRK, MATK, ROS, VEGFR2, FAK, JAK1, PDGFR-β, Lyn, TNK1, SCFR, Tie-2, and EGFR were increased ( Figure 8 A). We first selected proteins with consistent changes in KYSE150 and KYSE450 cells for verification and found that KRT15 can positively regulate the phosphorylation level of EphA3, but negatively regulate the phosphorylation of EGFR. Based on the fact that receptor tyrosine kinases mainly regulate the proliferation and differentiation of tumor cells through the PI3K-AKT pathway and the MAPK pathway, we focused on detecting the activation status of AKT and ERK. The results showed that after knocking down KRT15, ​​p-AKT was significantly downregulated, while p-ERK did not change significantly ( Fig. 9 ).

[0077] We used GST pull-down experiments combined with mass spectrometry to analyze proteins that interact with KRT15. GST and KRT15-GST fusion proteins were incubated with protein lysate of esophageal cancer cell KYSE150 and GST agarose beads, respectively, and separated by protein electrophoresis. Coomassie brilliant blue staining results showed that there were differential bands between the experimental group and the control group. High-abundance proteins and low-abundance proteins were cut out for mass spectrometry analysis ( Fig.10The mass spectrometry data were searched in the corresponding database using Proteome Discoverer1.4 software, and 901 proteins were finally obtained, of which 264 proteins were specifically detected in the KRT15-GST experimental group.

[0078] We performed gene enrichment analysis on the differentially expressed proteins, and the results showed that the proteins interacting with KRT15 were mainly involved in DNA metabolism ( Fig.11 ), including EGFR, MSH2, DDX11, MLH1, DKC1, CCT8, STOML2, NEK7, PCNA, EXOSC6, RAC1, among which EGFR, PCNA, and RAC1 have been reported to be involved in the occurrence and development of tumors. We used Co-IP combined with Western blot experiments to detect the expression of KRT15 and EGFR in the immunoprecipitation complex. The results suggested that KRT15 and EGFR were in the same complex ( Fig.12 ).

[0079] Materials and Methods

[0080] 1. Immunohistochemistry related experiments

[0081] (1) Tissue chip preparation

[0082] 1) Marking sections: Read the HE sections under a microscope and use a marker to mark at least 3 clear locations of cancer nests on the tumor tissue sections. Similarly, mark 2-3 morphologically normal locations on the paired normal tissue sections.

[0083] 2) Marking the paraffin block: Compare the HE sections and paraffin-embedded wax blocks of the same case, and use a marker pen to mark the location points to be sampled on the corresponding paraffin block according to the marks on the HE sections of the case.

[0084] 3) Preparation of receptor wax blocks: melt ordinary pathological paraffin at 65°C, precipitate it three times, add 3% refined beeswax, and prepare receptor wax blocks of appropriate size.

[0085] 4) Make tissue microarray: According to the arrangement of the designed tissue microarray, select a punching needle with a suitable aperture. Set the water bath temperature to 65°C, and place the melted paraffin in the mold. Select a suitable blank receptor wax block, punch holes in the blank wax block according to the pre-set coordinate position points, and discard the blank core. Then punch holes at the target position points of the tissue wax block to obtain samples, and move them into the pinholes punched in the receptor wax block. After the array is completed, use melted liquid paraffin to seal the exposed tissue.

[0086] 5) Sectioning: Place the prepared tissue microarray wax block in a 4°C refrigerator for 30 minutes, then cut a 4 μm thick white slice and stick it on a cationic anti-shedding sheet and place it in a 65°C drying oven overnight.

[0087] (2) Immunohistochemistry

[0088] 1) Dewaxing: Bake the tissue chip in a forced air oven at 68°C and 15 rpm for 2 hours to melt the paraffin, then quickly place it in a xylene solution and dewax for 15 minutes. Repeat this process 3 times.

[0089] 2) Hydration: The dewaxed tissue chip was immersed in 100%, 80%, and 70% ethanol for 5 minutes each to perform gradient hydration.

[0090] 3) Cleaning: Immerse the tissue chip in PBST solution, PBS buffer I, II, and III in sequence, and wash for 5 minutes each time.

[0091] 4) Antigen repair: Fill the antigen repair box with sodium citrate buffer (pH=6.0) or EDTA repair solution (pH=8.0 / pH=9.0), and preheat it in a microwave oven at high temperature for 3 minutes. Transfer the tissue chip to the preheated repair solution, heat it in a microwave oven at medium-low temperature for 20 minutes, and then cool it naturally to room temperature.

[0092] 5) Block endogenous peroxidase: Prepare 3% hydrogen peroxide in a dark place, then drop it onto the tissue chip and block it in a dark place for 15 minutes.

[0093] 6) Cleaning: Immerse the tissue chip in PBST solution, PBS buffer I, II, and III in sequence, with each cleaning lasting 5 minutes.

[0094] 7) Primary antibody incubation: Use a paraffin pencil to outline the edge of the tissue chip, dilute the antibody with primary antibody diluent, gently drip the antibody dilution onto the tissue surface to completely cover the tissue, and incubate in a wet box filled with water at 4°C overnight.

[0095] 8) Cleaning: Immerse the tissue chip in PBST solution, PBS buffer I, II, and III in sequence, with each cleaning lasting 5 minutes.

[0096] 9) PV9000 two-step detection I: Add reagent I (Polymer Helper) in the PV9000 detection kit to the tissue chip to completely cover the tissue, and place the slide in a humidified box and incubate at 37° C. for 20 minutes.

[0097] 10) Cleaning: Immerse the tissue chip in PBST solution, PBS buffer I, II, and III in sequence, and wash for 5 minutes each time.

[0098] 11) PV9000 two-step detection II: Add reagent II (Polyperoxidase-anti-mouse / rabbit IgG) in the PV9000 detection kit to the tissue chip to completely cover the tissue, and place the slide in a humidified box and incubate at 37°C for 30 minutes.

[0099] 12) Cleaning: Immerse the tissue chip in PBST solution, PBS buffer I, II, and III in sequence, with each cleaning lasting 5 minutes.

[0100] 13) DAB color development: Prepare DAB staining solution and add it dropwise to the tissue surface to completely cover the tissue. Observe the color development effect under a microscope. When the tissue is colored, remove the DAB solution immediately and place it in distilled water.

[0101] 14) Re-staining: Add hematoxylin stain solution to the tissue surface and rinse with running water after about 15 seconds.

[0102] 15) Blueing: Place the chip in 1% ammonia water for 8-10 minutes to allow the tissue to fully blue.

[0103] 16) Dehydration: The tissue chip was immersed in 75%, 85%, and 100% ethanol for 5 minutes each for gradient dehydration.

[0104] 17) Transparent: Immerse the tissue chip in a xylene washing tank for 10 minutes, repeat twice, and then place it in a fume hood to dry.

[0105] 18) Sealing: Add neutral sealing agent to the tissue chip and cover it with a cover glass for sealing.

[0106] 19) Observe under a microscope and use Nano Zoomer digital pathology slice scanner to scan the tissue chip and score each sample.

[0107] (3) Scoring principles

[0108] 1) Case exclusion principles: All or more than half of the same case in the tissue array delaminated; there were no cancer nests or normal epithelial tissues in the tissue; the number of tumor cells in the cancer nests was less than 100; the tumor cells in the cancer nests were vacuolated and shrunken; the tissue was dehydrated.

[0109] 2) Scoring criteria: First, determine the protein localization (nucleus, cytoplasm, cell membrane), identify the positive signal, and score according to the intensity and area of ​​the positive signal. The intensity is set at four levels: 0, 1, 2, and 3, and the area is set at three levels: 1, 2, and 3:

[0110] Strength Rating Area Rating No coloring: 0 points <20%: 1 point The signal is invisible under low magnification and appears light yellow under high magnification: 1 point ≥20%: 2 points The signal is visible under low magnification and brownish yellow under high magnification: 2 points ≥50%: 3 points The signal is visible under low magnification and dark brown under high magnification: 3 points

[0111] The score of each point is the score of intensity × area. The final score of each case is calculated as the average of multiple points. Cases with a score of 0 are defined as negative expression of the protein, and cases with a score of ≥3 are defined as positive expression.

[0112] 2. RNA in situ hybridization (Advanced Cell Diagnostics 2.5HD Visible Light Brown Detection Kit)

[0113] (1) Paraffin specimen pretreatment:

[0114] 1) Dewaxing: Bake the tissue chip in a forced air oven at 68°C and 15 rpm for 2 hours to melt the paraffin, then quickly place it in a xylene solution and dewax for 10 minutes. Repeat this process 3 times.

[0115] 2) Hydration: Immerse the dewaxed tissue chip in 100% ethanol for 2 minutes each time, twice in total, and then air-dry at room temperature.

[0116] 3) Block endogenous peroxidase: Add 5-8 drops of hydrogen peroxide to the tissue chip, react at room temperature for 10 minutes, and then wash twice in distilled water, 3 minutes each time.

[0117] 4) Processing target repair reagent: Prepare 1X target repair solution, boil it in a microwave oven, and then slowly place the tissue chip into the boiling repair solution and repair it for 15 minutes.

[0118] 5) Cleaning: Immediately wash the tissue chip in distilled water twice for 3 minutes each time, then immerse it in 75%, 85%, 100%, and 100% ethanol for 2 minutes each, and air-dry it thoroughly at room temperature.

[0119] 6) RNAScope protease treatment: Add about 3 drops of protease plus to each tissue chip, cover with plastic film, incubate at 40°C for 30 minutes, and then wash twice with distilled water for 3 minutes each time.

[0120] (2) RNAScope probe hybridization and amplification

[0121] 1) Pretreatment: dilute the washing buffer to 1x and place in a 40°C water bath for use; place the probe in a 40°C water bath for 10 minutes and then cool to room temperature; place Amp 1-6 in an ice box away from light for use.

[0122] 2) Hybridization: flick the slide to remove excess liquid, add about 4 drops of probe to completely cover the tissue, place in a wet box, and incubate in a 40°C incubator for 2 hours.

[0123] 3) Washing: Take out the hybridized slide and wash it twice with washing buffer, each time for 2 minutes.

[0124] (3) Enlarge

[0125] 1) Hybridization Amp1 (40°C for 30 minutes): flick the slide to remove excess liquid, add about 35 μL Amp 1 to completely cover each tissue, cover with plastic film and place in a humidified box at 40°C for 30 minutes, remove excess liquid, and then place the slide in 40 mL 1× washing buffer and shake wash twice, 2 minutes each time.

[0126] 2) Hybridization Amp2 (40°C for 15 minutes): flick the slide to remove excess liquid, add about 45 μL Amp 2 to completely cover each tissue, cover with plastic film and place in a wet box at 40°C for 15 minutes, remove excess liquid, and then place the slide in 40 mL 1× wash buffer and shake wash twice, 2 minutes each time.

[0127] 3) Hybridization Amp3 (40°C for 30 minutes): flick the slide to remove excess liquid, add about 35 μL Amp 3 to completely cover each tissue, cover with plastic film and place in a wet box at 40°C for 30 minutes, remove excess liquid, and then place the slide in 40 mL 1× wash buffer and shake wash twice, 2 minutes each time.

[0128] 4) Hybridization Amp4 (40°C for 15 minutes): flick the slide to remove excess liquid, add about 45 μL Amp 4 to completely cover each tissue, cover with plastic film and place in a wet box at 40°C for 15 minutes, remove excess liquid, and then place the slide in 40 mL 1× wash buffer and shake wash twice, 2 minutes each time.

[0129] 5) Hybridization of Amp5 (room temperature, preferably extended to 1 hour): flick the slide to remove excess liquid, add about 45μL Amp5 to completely cover each tissue, cover with plastic film and place in a wet box at 40℃ for 40 minutes to 1 hour, remove excess liquid, and then place the slide in 40mL 1× washing buffer and shake and wash twice, 2 minutes each time.

[0130] 6) Hybridization of Amp6 (room temperature for 15 minutes): flick the slide to remove excess liquid, add about 35 μL Amp6 to completely cover each tissue, cover with plastic film and place in a wet box at 40°C for 15 minutes, remove excess liquid, and then place the slide in 40 mL 1× wash buffer and shake wash twice, 2 minutes each time.

[0131] (4) Detection signal

[0132] 1) DAB color development: DAB-A solution and DAB-B solution were mixed in equal volumes to prepare DAB staining solution, and about 60 μL of DAB solution was added to each tissue section, covered with plastic film, and then incubated at room temperature for 10 minutes.

[0133] 2) Cleaning: Clean twice with distilled water, 5 minutes each time.

[0134] 3) Re-staining: Add hematoxylin solution to the tissue surface and rinse with running water after about 1 minute.

[0135] 4) Blueing: Place the chip in hot water at about 40-50℃ for about 5 minutes to allow the tissue to fully blue.

[0136] 5) Dehydration: Immerse the tissue chip in 100% ethanol for 2 minutes for dehydration, and repeat twice.

[0137] 6) Transparent: Immerse the tissue chip in a xylene washing tank for 30 minutes, repeat twice, and then place it in a fume hood to dry.

[0138] 7) Sealing: Add neutral sealing agent to the tissue chip and cover it with a cover glass for sealing.

[0139] 8) Observe under a microscope, scan the results using a chip scanner, and score each sample.

[0140] (5) Scoring principles

[0141] 1) Observe the tissue under a microscope: evaluate the morphological characteristics of the tissue and cells; evaluate the intensity of the positive control signal, which is small spots visible in the cells; determine the negative control background.

[0142] 2) Scoring criteria: Scoring is performed based on the intensity of the positive signal and the area of ​​the positive signal. The intensity is set at four levels: 0, 1, 2, and 3, and the area is set at three levels: 1, 2, and 3:

[0143] Strength Rating Area Rating 0 staining points or less than 1 signal point / 10 cells: 0 points <20%: 1 point 0-3 signal points / cell can be seen under 40x microscope: 1 point ≥20%: 2 points 4-10 signal points / cell visible under 40x microscope: 2 points ≥50%: 3 points >10 signal points / cell under 40x microscope: 3 points

[0144] The score of each point is the score of intensity × area. The final score of each case is calculated as the average of multiple points. Cases with a score of 0 are defined as negative expression of the protein, and cases with a score of ≥3 are defined as positive expression.

[0145] 3. Extraction of total RNA from cells (RNApure Tissue&Cell Kit CW0560)

[0146] 1) When the cells grow to 70-90% confluence, discard the original culture medium, wash twice with PBS, use trypsin to digest the cells, centrifuge at 1000 rpm for 3 minutes after the culture medium digestion is terminated, and collect the cell precipitate.

[0147] 2) Every 5×10 6 -1×10 7 Add 600 μL of buffer RL to the cells, pipette and beat several times to fully lyse them, and then leave them at room temperature for 5 minutes to completely separate the protein-nucleic acid complex.

[0148] 3) Centrifuge at 12,000 rpm for 2-5 minutes and collect the supernatant.

[0149] 4) Add 1 volume of 70% ethanol (prepared with RNase-free water) and mix well.

[0150] 5) Add all the above solution to the adsorption column in the collection tube. If the whole solution cannot be added to the adsorption column at one time, add it twice separately. Centrifuge at 12,000 rpm for 1 minute, discard the waste liquid in the collection tube and put it back into the collection tube.

[0151] 6) Pipette 350 μL of buffer RW1 solution into the adsorption column, centrifuge at 12,000 rpm for 15 seconds, discard the waste liquid and put the adsorption column back into the collection tube.

[0152] 7) Prepare DNase I mixed solution: add 8 μL 10× reaction buffer and 20 μL DNase I (1 U / μL) to 52 μL RNase-Free Water, mix well and prepare a reaction solution with a final volume of 80 μL.

[0153] 8) Pipette 80 μL of the prepared DNase I reaction solution and add it to the adsorption column. Incubate at 20-30°C for 15 minutes.

[0154] 9) Pipette 350 μL of buffer RW1 solution into the adsorption column, centrifuge at 12,000 rpm for 15 seconds, discard the waste liquid and put the adsorption column back into the collection tube.

[0155] 10) Add 500 μL of buffer RW2 solution (containing anhydrous ethanol) to the adsorption column, centrifuge at 12,000 rpm for 1 minute, discard the waste liquid in the collection tube, and then put the adsorption column back into the collection tube.

[0156] 11) Repeat the above steps.

[0157] 12) After centrifugation at 12,000 rpm for 2 minutes, discard the waste liquid in the collection tube. Then place the adsorption column at room temperature for several minutes to completely dry the adsorption column.

[0158] 13) Place the adsorption column in a new RNase-free centrifuge tube, add 30-50 μL of RNase-free water to the center of the adsorption column, place at room temperature for 1 minute, and then centrifuge at 12,000 rpm for 1 minute to collect the RNA solution.

[0159] 14) The RNA concentration was determined using Nanodrop software. A260 / 280 ratio greater than 2.0 was considered acceptable. RNA was stored at -70°C to prevent degradation.

[0160] 4. Reverse transcription (HiFiScript gDNA Removal RT MasterMix CW2020)

[0161] 1) Place RNase-free water, RT buffer, dNTP mixture, DTT, RNA template, primer mixture, and HiFiScript on ice for later use.

[0162] The reaction system was prepared as follows:

[0163]

[0164] 2) Vortex to mix, and centrifuge briefly to collect the solution on the tube wall to the bottom of the tube.

[0165] 3) cDNA synthesis reaction conditions:

[0166] 42℃ 30-50 minutes

[0167] 85℃ 5 minutes

[0168] 10℃ ∞

[0169] 4) After the reaction is completed, centrifuge briefly and cool on ice.

[0170] 5) The reverse transcription product can be directly used for PCR reaction and fluorescence quantitative PCR reaction, or stored at -20℃ for a long time.

[0171] 5. Target gene amplification (Takara HS DNA polymerase R010)

[0172] 1) Primer design targeting the full length of KRT15-CDS

[0173] Transcript: NM_002275.3

[0174] Forward primer: CCGGAATTCTAATGACCACCACATTTCTGCAAAAC (SEQ ID NO: 3)

[0175] Reverse primer: CCCAAGCTTTTAGATTTCTCTCTTGTGGGAAGAAACC (SEQ ID NO: 4)

[0176] 2) Prepare the PCR reaction system (50 μL) as follows:

[0177]

[0178] 3) Set up the PCR reaction program as follows:

[0179]

[0180] 4) Prepare agarose gel of corresponding concentration according to the size of PCR product fragments, and detect PCR products by electrophoresis.

[0181] 6. Recovery and purification of target gene PCR products

[0182] 1) Add 6× Loading buffer to the PCR product and separate the PCR products by agarose gel electrophoresis.

[0183] 2) Cut out the specific band of the target gene under the gel imager and weigh the gel block.

[0184] 3) According to the weight of the gel block, add binding buffer at a ratio of 1 μL / mg and place in a 65°C metal bath for 10 minutes until the gel block is fully dissolved.

[0185] 4) Transfer all the above solutions into the adsorption column, let it stand for 1 minute, centrifuge at 12,000 rpm for 1 minute, and discard the filtrate.

[0186] 5) Add 700 μL washing buffer, centrifuge at 12,000 rpm for 1 minute, and discard the filtrate.

[0187] 6) Repeat the above steps.

[0188] 7) Place at room temperature for 3 minutes and centrifuge at 12,000 rpm for 2 minutes to allow the alcohol to evaporate completely.

[0189] 8) Take out the adsorption column and put it into a new 1.5 mL EP tube. Add 50 μL RNAase-free water vertically to the center of the adsorption column. After standing for 10 minutes, centrifuge at 13,000 rpm for 2 minutes to collect the DNA solution.

[0190] 9) After the concentration is determined, it can be used for subsequent enzyme digestion reactions or stored at -20°C.

[0191] 7. Double restriction digestion of vector and target gene

[0192] 1) Prepare the double enzyme digestion system (50 μL) as follows:

[0193] 10×Buffer (select according to enzyme digestion combination) 5μL Plasmid DNA or KRT15-CDS XμL Restriction endonuclease 1 1μL (1μg DNA corresponds to 1μL restriction enzyme) Restriction endonuclease 2 1μL (1μg DNA corresponds to 1μL restriction enzyme) <![CDATA[ddH2O]]> Up to 50 μL

[0194] 2) Enzyme digestion was performed at 37°C for 2 hours, and the double enzyme digestion effect was detected by agarose electrophoresis. The plasmid DNA and target gene fragments were recovered and purified, and the DNA concentration was determined.

[0195] 8. Connect the vector to the target gene

[0196] 1) The recovered plasmid DNA and KRT15-CDS fragment were mixed at a molar mass ratio of 1:3-1:5 to a total volume of 5 μL, and an equal volume of solution I was added.

[0197] 2) Ligate at 16°C for 4 hours or overnight.

[0198] 9. Bacterial transformation

[0199] 1) Take 8 μL of the ligation product and add it to 50 μL of DH5α competent cells melted on ice and mix well.

[0200] 2) Place on ice for 30 minutes, heat shock at 42°C for 45 seconds, and quickly place on ice for 2 minutes.

[0201] 3) Add 600 μL of LB medium without antibiotics to the competent cells, place in a 37°C constant temperature shaker, and culture at 190 rpm for 60 minutes.

[0202] 4) Take out 400 μL of bacterial solution and use a spreader to evenly apply it on the LB plate containing antibiotics. After the bacterial solution is completely absorbed, invert and culture it in an incubator at 37°C overnight for 12-16 hours.

[0203] 5) Pick a single clone for bacterial liquid PCR identification.

[0204] 10. PCR identification of bacterial liquid

[0205] 1) Pick 5 single colonies and place them in 1 mL of LB medium containing antibiotics. Culture them overnight at 37°C and 220 rpm.

[0206] 2) Pipette 200 μL of bacterial solution, centrifuge at 12,000 rpm for 1 minute, and discard the supernatant.

[0207] 3) Add 50 μL of nuclease-free water, boil at 98°C for 5 minutes, aspirate the supernatant, and obtain plasmid DNA.

[0208] 4) Prepare the bacterial solution PCR system (20 μL) as follows:

[0209]

[0210]

[0211] 5) Set up the PCR reaction program as follows:

[0212]

[0213] 6) Prepare agarose gel of corresponding concentration according to the size of PCR product fragments, and identify the PCR products by electrophoresis.

[0214] 7) Take 200 μL of the bacterial solution with positive PCR results and send it to the company for sequencing identification.

[0215] 8) Add 20% glycerol to the bacterial solution that has been successfully identified by sequencing for seed preservation and store it at -80°C.

[0216] 11. Plasmid extraction (EndoFree Plasmid Midi Kit CW2105)

[0217] 1) Transfer 5-15 mL of overnight culture to a 10 mL centrifuge tube, centrifuge at 3,000 rpm at 4°C for 15 minutes, and discard the supernatant.

[0218] 2) Resuspend the bacterial pellet in 1 mL of 1× PBS, transfer to a 1.5 mL centrifuge tube, centrifuge at 13,000 rpm for 1 minute, carefully discard all the supernatant, and collect the bacterial pellet.

[0219] 3) Add 500 μL of buffer P1 solution (containing RNase A) to resuspend the bacterial pellet.

[0220] 4) Add 500 μL of buffer P2 solution to the centrifuge tube, gently mix by inverting up and down 8-10 times to fully lyse the bacteria, and then leave at room temperature for 3-5 minutes.

[0221] 5) Add 500 μL of buffer E3 solution to the centrifuge tube, mix immediately by inverting 8-10 times, and leave at room temperature for 5 minutes. Centrifuge at 13,000 rpm for 5 minutes and aspirate the supernatant.

[0222] 6) Add the supernatant to the filter column, centrifuge at 13,000 rpm for 1 minute, and then transfer the filtrate in the collection tube to a centrifuge tube.

[0223] 7) Add 450 μL of isopropanol to the collected filtrate and mix by inverting.

[0224] 8) Column equilibration: Add 200 μL of buffer PS solution to the adsorption column (including the collection tube), centrifuge at 13,000 rpm for 2 minutes, discard the waste liquid and put the adsorption column back into the collection tube.

[0225] 9) Transfer the mixed solution from step 7 to the equilibrated adsorption column.

[0226] 10) Centrifuge at 13,000 rpm for 1 minute, discard the waste liquid in the collection tube, and then put the adsorption column back into the collection tube.

[0227] 11) Add 750 μL of buffer PW solution (with anhydrous ethanol added) to the adsorption column, centrifuge at 13,000 rpm for 1 minute, and discard the waste liquid in the collection tube.

[0228] 12) Place the adsorption column back into the collection tube and centrifuge at 13,000 rpm for 1 minute.

[0229] 13) Place the adsorption column in a new centrifuge tube (self-prepared), draw 100-200 μL Endo-Free buffer EB and add it to the middle part of the adsorption membrane in mid-air, place it at room temperature for 15 minutes, and then centrifuge it at 13,000 rpm for 2 minutes.

[0230] 14) Repeat step 12) to obtain plasmid DNA, determine the plasmid concentration, and store at -20°C.

[0231] 12. Experiments related to the construction of PLKO-shKRT15 lentiviral vector

[0232] (1) Design of shKRT15 oligonucleotide

[0233] Forward Oligonucleotide:

[0234] 5'

[0235] CCGGGAAGCCGAAGTATCTCAGCTTCTCGAGAAGCTGAGATCTTCGGCTTC-TTTTTG 3' (SEQ IDNO: 5);

[0236] Reverse Oligonucleotide:

[0237] 5'

[0238] AATTCAAAAAGAAGCCGAAGTATCTCAGCTTCTCGAGAAGCTGAGATCTTCGGCTTC 3' (SEQ ID NO: 6).

[0239] (2) shRNA oligonucleotide annealing

[0240] 1) Centrifuge the newly synthesized shRNA oligonucleotide at 12,000 rpm for 10 min to prevent it from spilling after opening the lid.

[0241] 2) Dilute the oligonucleotide to 20 μmol / L using nuclease-free water.

[0242] 3) Prepare the annealing system (50 μL) as follows:

[0243]

[0244] 4) Set the reaction program as follows to perform gradient cooling to anneal the oligonucleotides:

[0245]

[0246] (3) Enzyme digestion of PLKO.1 vector and recovery and purification

[0247] 1) Prepare the double enzyme digestion system (50 μL) as follows:

[0248]

[0249] 2) Enzyme digestion was performed at 37°C for 2 hours, and the double enzyme digestion effect was detected by agarose electrophoresis. The plasmid DNA was recovered and purified, and the DNA concentration was determined.

[0250] (4) Connection

[0251] 1) Prepare the connection system as follows:

[0252] 3 μL of annealed oligonucleotides

[0253] Enzyme-cut vector XμL (50ng)

[0254] Solution I 3+XμL

[0255] 2) Ligate at 16°C for 4 hours or overnight.

[0256] 3) Take part of the ligation product to transform TransStble 3 competent cells, pick a single clone, and extract the plasmid after sequencing and confirmation.

[0257] 13. Western blot experiment

[0258] (1) Cell protein extraction

[0259] 1) When the cells grow to 80-90% confluence, discard the original culture medium, wash twice with 1×PBS, carefully scrape the cells with a cell spatula, add an appropriate amount of 1×PBS solution to collect the cells, centrifuge at 1,000 rpm for 3 minutes, discard the supernatant, and obtain the cell pellet.

[0260] 2) Add an appropriate amount of RIPA lysis buffer containing protease and phosphatase inhibitors and lyse on ice for 30 minutes.

[0261] 3) Centrifuge at 12,000 rpm and 4°C for 20 minutes, carefully pipette the protein supernatant into a new 1.5 mL EP, and store the mixture at -80°C.

[0262] (2) BCA protein quantification (ThermoFisher BCA Protein Assay Kit 23227)

[0263] 1) Prepare BCA working solution: Prepare the working solution according to the ratio of regent A:regent B=50:1 and mix thoroughly.

[0264] 2) Preparation of protein standards: Use protein lysis buffer to gradiently dilute the standard BSA stock solution to set the concentrations to 0 μg / μL, 0.25 μg / μL, 0.5 μg / μL, 1 μg / μL, and 2 μg / μL.

[0265] 3) Take 1 μL of the standard or sample to be tested and add it to a 96-well plate. Add 99 μL of BCA working solution to each well, shake gently to mix thoroughly, and incubate at 37°C for 30 minutes.

[0266] 4) Use an ELISA reader to measure the absorbance at a wavelength of 570 nm.

[0267] 5) Draw a standard curve based on the absorbance value of the BSA standard. Calculate the protein concentration of the sample to be tested based on the standard curve and the absorbance value of the sample.

[0268] (3) SDS-PAGE electrophoresis and protein blotting

[0269] 1) Gel preparation: Set up a clean and dried glass plate, prepare SDS-PAGE separation gel of corresponding concentration according to the molecular weight of the target protein, gently pour it into the glass plate, then add Millipore ultrapure water for water sealing, let it stand at room temperature for 1 hour, wait for a flat boundary to appear between the separation gel and the water, remove the water layer, and dry it with filter paper. Prepare 5% concentrated gel, gently add the upper layer of the separation gel, and insert the sample comb. Let it stand at room temperature for 1 hour. After the concentrated gel solidifies, assemble the gel glass into the electrophoresis tank, inject the electrophoresis buffer, let it stand for 5 minutes to observe whether there is leakage, then carefully pull out the comb, repeatedly rinse the loading hole with electrophoresis buffer, and prepare for loading.

[0270] 2) Electrophoresis: Take the same mass of protein samples, add 5× protein loading buffer, mix well, denature at 100℃ for 10 minutes, cool on ice and centrifuge immediately, and carefully add the samples to the sample wells. Electrophoresis conditions: 80V, 30 minutes; 100V, electrophoresis until bromophenol blue reaches 5mm from the bottom edge of the glass plate.

[0271] 3) Protein blotting: After the electrophoresis is completed, use a wedge-shaped tool to remove the gel and soak it in transfer buffer. Cut the PVDF membrane and Whatman 3M filter paper to 5.2cm×8.4cm in size, soak the PVDF membrane in methanol for 5 seconds, soak it in ultrapure water for 5 minutes, and then transfer it to the transfer buffer. After the filter paper, PVDF membrane, and gel are soaked in the transfer buffer for 10 minutes, place the sponge, filter paper, PVDF membrane, separation gel, filter paper, sponge in the order of anode to cathode, and then put it into the transfer tank with transfer buffer, and transfer the membrane at a constant current of 220mA for 2 hours in an ice water bath.

[0272] 4) Target protein blocking and antibody incubation: After the transfer, quickly remove the PVDF membrane and place it in a blocking solution (5% skim milk) for 1 hour; use the blocking solution to prepare the target protein antibody dilution solution according to the ratio in the instructions, and hybridize the antigen and antibody at 4°C overnight; recover the primary antibody, rinse the target band with membrane washing buffer TBST, each time for 6 minutes, wash 4 times; add the secondary antibody dilution corresponding to the source species of the primary antibody, incubate at room temperature for 1 hour; rinse the target band with TBST 4 times, each time for 6 minutes. The antibodies used are as follows: KRT15 (Abcam ab52816), p-EphA3 (Y527) (Abcam ab191565), EphA3 (Santa sc514209), p-AKT (S473) (CST 4060), AKT (CST 4691), p-ERK1 / 2 (Y202 / T204) (CST 4370), ERK1 / 2 (CST4695), p-EGFR (Y1068) (CST 3777), EGFR (Proteintech18986-1-AP).

[0273] 5) Detection of target protein: Mix equal volumes of ECL solution A and solution B, evenly drop them on the PVDF membrane, and then use LAS4000 exposure machine for exposure and development.

[0274] 6) Elution of the target protein: After exposure, place the target protein band in the elution buffer and elute on a shaker for 30 minutes, then rinse with TBST three times, 10 minutes each time. After blocking, incubate with a new primary antibody for the next round of target protein detection.

[0275] 14. GST pull-down related experiments

[0276] (1) Expression and purification of GST-fused target protein

[0277] 1) Empty pGEX-KG and plasmid pGEX-KG-KRT15 were used to transform competent cells BL21(DE3).

[0278] 2) The transformed BL21(DE3) bacteria were inoculated into LB medium containing ampicillin and cultured overnight in a shaking incubator at 37°C and 220 rpm.

[0279] 3) The bacterial solution was inoculated into 100 mL LB medium (containing ampicillin), and cultured at 37°C and 220 rpm until the OD value of the bacterial solution reached about 0.6. Then 1 mmol / L IPTG was added and induced for expression at 25°C and 180 rpm for 8 hours.

[0280] 4) Transfer the bacterial solution to a sterile 50 mL centrifuge tube, centrifuge at 3,000 rpm for 10 minutes at 4°C, remove the supernatant to obtain the bacterial pellet, wash twice with 1× PBS, add an appropriate amount of PBST containing 1% Triton-100 according to the amount of bacterial pellet, and add protease inhibitors and lysozyme in proportion, and sonicate on ice until the solution is clear (ultrasonic conditions: 80 W, working for 10 seconds, rest for 15 seconds).

[0281] 5) Centrifuge at 12,000 rpm for 20 minutes under low temperature conditions and collect the supernatant to obtain the protein.

[0282] 6) SDS-PAGE gel electrophoresis combined with Coomassie Brilliant Blue staining was used to detect whether the fusion protein was successfully expressed.

[0283] (2) GST pull-down experiment

[0284] 1) Take equal amounts of pGEX-KG empty-GST and pGEX-KG-KRT15-GST fusion protein solutions, add 40 μL GST agarose beads respectively, and incubate at 4°C for 6 hours.

[0285] 2) After instant centrifugation, remove the supernatant and carefully add an appropriate amount of 1×PBS to wash the GST agarose beads 4-5 times for later use.

[0286] 3) Use non-denaturing lysis buffer to lyse a sufficient amount of cells (about 6-8 10 cm culture dishes with a confluence of 90%), centrifuge at 13,000 rpm for 20 minutes at 4°C, take the supernatant, determine the concentration and set aside.

[0287] 4) The cell protein solution was divided into two equal parts, mixed with GST agarose beads bound to pGEX-KG empty fusion protein and GST agarose beads bound to pGEX-KG-KRT15 fusion protein, respectively, and incubated overnight at 4°C with rotation.

[0288] 5) After instant centrifugation, remove the supernatant, wash the GST agarose beads once with non-denaturing lysis buffer, and then wash the GST agarose beads 4-5 times with an appropriate amount of 1× PBS.

[0289] 6) Add 2× protein loading buffer, heat at 100° C. for 5 minutes, centrifuge briefly to obtain a collection of proteins interacting with KRT15, ​​and then separate them by SDS-PAGE electrophoresis.

[0290] 7) After staining with Coomassie Brilliant Blue and decolorization, the blank group was used as the control, and the difference bands of the two groups were cut out respectively, and the high-abundance proteins and low-abundance proteins were stored separately for subsequent mass spectrometry identification. The mass spectrometry identification was completed by Zhongke Xinsheng.

[0291] 15. Experiments related to cell level

[0292] (1) Eukaryotic cell transfection with siRNA / plasmid DNA (Invitrogene Lipofectamine 2000 Transfection Reagent 11668019)

[0293] 1) siRNA sequence:

[0294]

[0295] 2) Cells in the logarithmic growth phase were inoculated into six-well plates and cultured at 37° C. for 16-18 hours. The confluence of the cells after attachment reached 30%-50%.

[0296] 3) Prepare the reaction reagents as follows:

[0297] 5μL lipofectamine 2000+250μL oppoti-MEM

[0298] 5μL siRNA (100pmol) / 2.5μg plasmid DNA + 250μL oppoti-MEM

[0299] Incubate at room temperature for 5 minutes

[0300] 4) Gently mix the diluted transfection reagent and siRNA / plasmid DNA and incubate at room temperature for 20 minutes to form a transfection complex.

[0301] 5) Cell medium replacement: discard the original cell culture medium, wash twice with PBS restored to room temperature, then wash one to two times with serum-free and antibiotic-free RPMI 1640 culture medium, then add 2 mL of serum-free and antibiotic-free RPMI 1640 culture medium, and drop the transfection complex into the culture plate.

[0302] 6) After culturing at 37°C for 6 hours, the complete culture medium was replaced to terminate the transfection. After further culturing for 48 hours, the cells were collected and the knockdown of the target protein was detected by Western blot.

[0303] (2) Construction of stable knockdown cell lines

[0304] 1) HEK293FT cells in good growth condition were seeded in a 6 cm cell culture dish and cultured at 37°C for 16-18 hours.

[0305] 2) When the cells adhered to the wall and grew to a confluence of 70%, the virus packaging plasmid and PLKO.1-shKRT15 plasmid were transfected into KEK293FT cells. The transfection steps were the same as above. The transfection system was as follows:

[0306]

[0307] Lipofectamine 2000 18μL lipofectamine 2000 added to 500μL Oppoti-MEM medium

[0308] 3) After transfection, the cells were cultured at 37°C for 6 hours, and then the original culture medium was discarded and 3 mL of DMEM medium containing 30% FBS was added to continue the culture.

[0309] 4) Collect the virus supernatant every 24 hours and store at 4°C for a total of two collections.

[0310] 5) Combine the virus supernatants collected twice, then filter using a 0.22 μm filter membrane. After packaging, they can be stored at 4°C for short-term storage or -80°C for long-term storage.

[0311] 6) Infection of target cells with viral supernatant: Target cells to be infected are seeded into six-well plates 24 hours before infection. When the confluence reaches 50%, 1 mL of fresh complete medium is replaced, and then 0.5 mL of viral supernatant and 8 μg / mL of polybrene are added.

[0312] 7) After culturing at 37°C for 12 hours, the medium was replaced with fresh complete medium. After further culturing for 24 hours, the cells were passaged at a ratio of 1:3.

[0313] 8) Determine the killing concentration of puromycin in target cells: Target cells in good growth state are seeded in a 24-well plate. When the confluence reaches 50%, puromycin working solution is prepared at concentrations of 0, 0.5, 1, 2, and 4 μg / mL, and then added to the cells. After culturing for 3 days, the cell state is observed. The group without puromycin is used as the negative control, and the concentration at which all cells die after 3 days of treatment is selected as the killing concentration of target cells.

[0314] 9) Puromycin was added for screening according to the determined killing concentration, and a negative control was set up. Stable knockdown cells were obtained after culturing at 37°C for three days.

[0315] (3) Cell proliferation ability detection

[0316] 1) Cultivate cells to the logarithmic growth phase, use trypsin to digest the cells, and then add complete culture medium to terminate the digestion to obtain a cell suspension.

[0317] 2) Take 10 μL of cell suspension and add it to a cell counting plate, and count using a bio-rad counter.

[0318] 3) Calculate the volume of cell suspension required for each group of cells, dilute the cells with RPMI1640 complete medium, and adjust the cell density to 2×10 4 Pieces / mL.

[0319] 4) Take 100 μL of the cell suspension and inoculate it into a 96-well plate, that is, inoculate 2000 cells per well, set up 4 replicate wells in each group, inoculate 6 plates in total, and place them in a 37°C incubator containing 5% CO2 for culture.

[0320] 5) When the cells are completely attached, take out a 96-well plate for CCK8 detection: prepare CCK8 working solution according to the ratio of serum-free and antibiotic-free RPMI medium: CCK8 = 10:1, discard the original medium in the 96-well plate, add CCK8 working solution to the medium in each well, shake and mix, place in a 37°C incubator in the dark for 1 hour, and then use a microplate reader to detect the absorbance value of the cells at 450nn (i.e., OD450 value), and define this plate as 0 day.

[0321] 6) Take out one 96-well plate every 24 hours to detect the OD450 value of the cells, and obtain the OD450 values ​​of six time points from 0 to 5 days.

[0322] 7) Data analysis: Calculate the average OD450 value of each group of cells on days 0-5 and set it as the vertical axis, and plot the cell growth curve with days as the horizontal axis.

[0323] (4) Cell cycle distribution detection (Tongren Chemical Cell Cycle Assay Kit C543)

[0324] 1) Wash the cells to be tested with PBS, then digest them with trypsin. After the culture medium is terminated, collect the cell suspension, centrifuge at 1,000 rpm for 3 minutes, and discard the supernatant to obtain the cell pellet.

[0325] 2) Resuspend the cell pellet in PBS and centrifuge at 1,000 rpm for 3 minutes. Repeat this process.

[0326] 3) Add 150 μL PBS to resuspend the cell pellet, add 350 μL pre-cooled anhydrous ethanol dropwise, and fix at 4°C overnight.

[0327] 4) Take out the tube the next day, return it to room temperature, centrifuge it at 1,000 rpm for 3 minutes, and discard the supernatant.

[0328] 5) Resuspend the cell pellet in PBS, centrifuge at 1,000 rpm for 3 minutes, and collect the cell pellet.

[0329] 6) Add 400 μL of freshly prepared PI working solution containing 50 μg / mL RNase under light-proof conditions and react at room temperature for 30 minutes.

[0330] 7) Flow cytometer testing.

[0331] 8) Data analysis was performed using Modifit software: forward scattered light (FSC) and side scattered light (SSC) gating was used to circle the cells to be analyzed, adherent cells were excluded by PI-W / PI-A gating, single cells in the FSC / SSC and PI-W / PI-A gates were obtained, and the percentage of cells in each stage of the cell cycle was determined.

[0332] (5) Detection of cell apoptosis level (Annexin V, FITC Apoptosis Detection Kit AD10 from Tongren Chemical)

[0333] 1) Wash the cells to be tested with PBS, then digest them with EDTA-free trypsin. After the culture medium is terminated, collect the cell suspension, centrifuge at 1,000 rpm for 3 minutes, and discard the supernatant to obtain the cell pellet.

[0334] 2) Resuspend the cell pellet in pre-cooled PBS and centrifuge at 1,000 rpm for 3 minutes. Repeat this process.

[0335] 3) According to the kit instructions, add 100 μL binding buffer to resuspend the cell pellet. The number of cells is about 1×10 5 indivual.

[0336] 4) Add 5 μL Annexin V and FITC respectively in the dark and react at room temperature for 15 minutes.

[0337] 5) Add 400 μL binding buffer before loading, and then use flow cytometry for detection.

[0338] 16. Nude mouse subcutaneous transplant tumor formation experiment

[0339] 1) After esophageal cancer cells stably expressing PLKO.1-sh non-silencing and PLKO.1-shKRT15 were cultured to a sufficient number, the cells were trypsinized and the culture was terminated by adding complete culture medium.

[0340] 2) Mix the cell suspension thoroughly, take 20 μL of cells and add them to the cell plate, and count them using a bio-rad counter.

[0341] 3) Calculate the total number of cells based on the cell concentration and the volume of culture medium added.

[0342] 4) Add 1× PBS solution to make the cell suspension concentration 1×10 7 Pieces / mL.

[0343] 5) Nude mice were divided into a non-silencing group and a knockdown group according to their body weight, and 100 μL of cell suspension (i.e., 1×106 cells / mouse) was subcutaneously inoculated into the right armpit of nude mice.

[0344] 6) The length and width of the subcutaneous tumor were measured every two days using a vernier caliper, and the tumor volume was calculated (length×width×width×π / 6).

[0345] 7) When the subcutaneous tumor volume of the non-silencing group of nude mice reached 1,000 mm3, the experiment was terminated, the mice were killed by cervical dislocation, the tumor tissues were removed, weighed and photographed, and the changes in tumor volume, tumor weight, and nude mouse body weight were plotted.

[0346] References

[0347] Chong,LY,Cheok,PY,Tan,WJ,Thike,AA,Allen,G.,Ang,MK,Ooi,AS,Tan,P.,Teh,BT,and Tan,PH(2012).Keratin 15,transcobalamin I and homeoboxgene Hox-B13 expression in breast phyllodes tumors:novel markers inbiological classification.Breast Cancer Res Treat 132,143-151.

[0348] Folgueira,MA,Brentani,H.,Katayama,ML,Patrao,DF,Carraro,DM,Mourao Netto,M.,Barbosa,EM,Caldeira,JR,Abreu,AP,Lyra,EC,et al.(2006).Gene expression profiling of clinical stages II and III breast cancer.Braz JMed Biol Res 39,1101-1113.

[0349] Giroux,V.,Lento,A.A.,Islam,M.,Pitarresi,J.R.,Kharbanda,A.,Hamilton,K.E.,Whelan,K.A.,Long,A.,Rhoades,B.,Tang,Q.,et al.(2017).Long-lived keratin15+esophageal progenitor cells contribute to homeostasis and regeneration.JClin Invest 127,2378-2391.

[0350] Giroux,V.,Stephan,J.,Chatterji,P.,Rhoades,B.,Wileyto,E.P.,Klein-Szanto,A.J.,Lengner,C.J.,Hamilton,K.E.,and Rustgi,A.K.(2018).Mouse IntestinalKrt15+Crypt Cells Are Radio-Resistant and Tumor Initiating.Stem CellReports10,1947-1958.

[0351] Gomez-Morales,M.,Camara-Pulido,M.,Miranda-Leon,M.T.,Sanchez-Palencia,A.,Boyero,L.,Gomez-Capilla,J.A.,and Farez-Vidal,M.E.(2013).Differentialimmunohistochemical localization of desmosomal plaque-related proteins innon-small-cell lung cancer.Histopathology 63,103-113.

[0352] Jih,D.M.,Lyle,S.,Elenitsas,R.,Elder,D.E.,and Cotsarelis,G.(1999).Cytokeratin 15 expression in trichoepitheliomas and a subset of basal cellcarcinomas suggests they originate from hair follicle stem cells.J CutanPathol 26,113-118.

[0353] North,J.P.,McCalmont,T.H.,Fehr,A.,van Zante,A.,Stenman,G.,and LeBoit,P.E.(2015).Detection of MYB Alterations and Other Immunohistochemical Markersin Primary Cutaneous Adenoid Cystic Carcinoma.Am J Surg Pathol 39,1347-1356.

[0354] Omary,M.B.,Coulombe,P.A.,and McLean,W.H.(2004).Intermediate filamentproteins and their associated diseases.N Engl J Med 351,2087-2100.

[0355] Omary,M.B.,Ku,N.O.,Strnad,P.,and Hanada,S.(2009).Toward unravelingthe complexity of simple epithelial keratins in human disease.J Clin Invest119,1794-1805.

[0356] Pal, SK, Sakamoto, K., Aragaki, T., Akashi, T., and Yamaguchi, A. (2013).Theexpression profiles of acidic epithelial keratins in ameloblastoma.Oral SurgOral Med Oral Pathol Oral Radiol 115,523-531.

[0357] Gene expression profilingreveals novel biomarkers in nonsmall cell lung cancer.Int J Cancer 129,355-364.

[0358] Schweizer , J , Bowden , PE , Coulombe , PA , Langbein , L , Lane , EB , Magin , TM , Maltais , L , Omary , MB , Parry , DA , Rogers , MA , and Wright , MW(2006).Newconsensus nomenclature for mammalian keratins.J Cell Biol174,169-174.

[0359] Tai, G., Ranjzad, P., Marriage, F., Rehman, S., Denley, H., Dixon, J., Mitchell, K., Day, PJ, and Woolf, AS(2013). 8,e81167.

[0360] Waseem,A.,Dogan,B.,Tidman,N.,Alam,Y.,Purkis,P.,Jackson,S.,Lalli,A.,Machesney,M.,and Leigh,IM(1999).Keratin 15 expression in stratified epithelia:downregulation in activated keratinocytes.J Invest Dermatol 112,362-369.

[0361] Yang, R., Zheng, Y., Burrows, M., Liu, S., Wei, Z., Nace, A., Guo, W., Kumar, S., Cotsarelis, G., and Xu, X. (2014). Generation of folliculogenic human epithelialstem cells from induced pluripotent stem cells. Nat Commun 5, 3071.

[0362] Zekri,AN,El-Sisi,ER,Abdallah,ZF,Ismail,A.,and Barakat Barakat,A.(2017).Gene expression profiling of circulating CD133(+)cells ofhepatocellular carcinoma patients associated with HCV infection.J Egypt NatlCanc Inst 29,19-24. Sequence Listing <110> Cancer Hospital of Chinese Academy of Medical Sciences <120> Application of KRT15 in auxiliary diagnosis and targeted therapy of esophageal cancer <130> 300267CG <160> 10 <170> SIPOSequenceListing 1.0 <210> 1 <211> 1371 <212> DNA <213> Homo sapiens <400> 1 60. atgaccacca catttctgca aacttcttcc tccaccttttg ggggtggctc aacccgaggg ggttccctcc tggctgggggg aggtggcttt ggtgggggg gtctctctgg gggaggtgga 120 agccgaagta tctcagcttc ttctgctagg tttgtctctt cagggtcagg aggaggatat gggggtggca tgagggtctg tggctttggt ggaggggctg gtagtgtttt cggtggaggc 240 tttggagggg gcgttggtgg gggttttggt ggtggctttg gtggtggcga tggtggtctc 300 360. ctctctggca atgagaaaat taccatgcag aacctcaatg accgcctggc ctcctacctg gacaaggtac gtgccctgga ggaggccat gctgacctgg aggtgaagat ccatgactgg 480. taccagaagc agaccccaac cagcccaga tgcgactaca gccaatactt caagaccatt gaagagctcc gggacaagat catggccacc accatcgaca actcccgggt catcctggag 540 atcgacaatg ccaggctggc tgcggacgac ttcaggctca agtatgagaa tgagctggcc ctgcgccagg gcgttgaggc tgacatcaac ggcttgcgcc gagtcctgga tgagctgacc 660 ctggccagga ctgacctgga gatgcagatc gagggcctga atgaggagct agcctacctg 720 aagagaacc acgagagga gatgaggag ttcagcagcc agctggccgg ccaggtcaat 780 gtggagatgg acgcagcacc gggtgtggac ctgacccgtg tgctggcaga gatgagggag 840 cagtacgagg ccatggcgga gagaaccgc cgggatgtcg aggctggtt cttcagcaag 900 actgaggagc tgaacaaga ggtggcctcc aacacagaaa tgatccagac cagcagacg 960 gagatcacag acctgagacg cacgatgcag gagctggaga tcgagctgca gtcccagctc 1020 agcatgaaag ctgggctgga gaactcactg gccgagacag agtgccgcta tgccacgcag 1080 ctgcagcaga tccaggggct cattggtggc ctggaggccc agctgagtga gctccgatgc 1140 gagatggagg ctcagaacca ggagtacaag atgctgcttg actaagac acggctggag 1200 caggagatcg ctacttaccg cagcctgctc gagggccagg atgccagat ggctggcatt 1260 gccatcagggg aagcccttc aggaggtggt ggtagcagca gcaatttcca catcaatgta 1320 gaagagtcag tggatggaca ggtggttct tcccacaga gagaaatcta a 1371 <210> 2 <211> 456 <212> PRT <213> Homo sapiens <400> 2 Met Thr Thr Thr Phe Leu Gln Thr Ser Ser Ser Thr Phe Gly Gly Gly 1 5 10 15 Ser Thr Arg Gly Gly Ser Leu Leu Ala Gly Gly Gly Gly Phe Gly Gly 20 25 30 Gly Ser Leu Ser Gly Gly Gly Gly Ser Arg Ser Ile Ser Ala Ser Ser 35 40 45 Ala Arg Phe Val Ser Ser Gly Ser Gly Gly Gly Tyr Gly Gly Gly Met 50 55 60 Arg Val Cys Gly Phe Gly Gly Gly Ala Gly Ser Val Phe Gly Gly Gly 65 70 75 80 Phe Gly Gly Gly Val Gly Gly Gly Phe Gly Gly Gly Phe Gly Gly Gly 85 90 95 Asp Gly Gly Leu Leu Ser Gly Asn Glu Lys Ile Thr Met Gln Asn Leu 100 105 110 Asn Asp Arg Leu Ala Ser Tyr Leu Asp Lys Val Arg Ala Leu Glu Glu 115 120 125 Ala Asn Ala Asp Leu Glu Val Lys Ile His Asp Trp Tyr Gln Lys Gln 130 135 140 Thr Pro Thr Ser Pro Glu Cys Asp Tyr Ser Gln Tyr Phe Lys Thr Ile 145 150 155 160 Glu Glu Leu Arg Asp Lys Ile Met Ala Thr Thr Ile Asp Asn Ser Arg 165 170 175 Val Ile Leu Glu Ile Asp Asn Ala Arg Leu Ala Ala Asp Asp Phe Arg 180 185 190 Leu Lys Tyr Glu Asn Glu Leu Ala Leu Arg Gln Gly Val Glu Ala Asp 195 200 205 Ile Asn Gly Leu Arg Arg Val Leu Asp Glu Leu Thr Leu Ala Arg Thr 210 215 220 Asp Leu Glu Met Gln Ile Glu Gly Leu Asn Glu Glu Leu Ala Tyr Leu 225 230 235 240 Lys Lys Asn His Glu Glu Glu Met Lys Glu Phe Ser Ser Gln Leu Ala 245 250 255 Gly Gln Val Asn Val Glu Met Asp Ala Ala Pro Gly Val Asp Leu Thr 260 265 270 Arg Val Leu Ala Glu Met Arg Glu Gln Tyr Glu Ala Met Ala Glu Lys 275 280 285 Asn Arg Arg Asp Val Glu Ala Trp Phe Phe Ser Lys Thr Glu Glu Leu 290 295 300 Asn Lys Glu Val Ala Ser Asn Thr Glu Met Ile Gln Thr Ser Lys Thr 305 310 315 320 Glu Ile Thr Asp Leu Arg Arg Thr Met Gln Glu Leu Glu Ile Glu Leu 325 330 335 Gln Ser Gln Leu Ser Met Lys Ala Gly Leu Glu Asn Ser Leu Ala Glu 340 345 350 Thr Glu Cys Arg Tyr Ala Thr Gln Leu Gln Gln Ile Gln Gly Leu Ile 355 360 365 Gly Gly Leu Glu Ala Gln Leu Ser Glu Leu Arg Cys Glu Met Glu Ala 370 375 380 Gln Asn Gln Glu Tyr Lys Met Leu Leu Asp Ile Lys Thr Arg Leu Glu 385 390 395 400 Gln Glu Ile Ala Thr Tyr Arg Ser Leu Leu Glu Gly Gln Asp Ala Lys 405 410 415 Met Ala Gly Ile Ala Ile Arg Glu Ala Ser Ser Gly Gly Gly Gly Ser 420 425 430 Ser Ser Asn Phe His Ile Asn Val Glu Glu Ser Val Asp Gly Gln Val 435 440 445 Val Ser Ser His Lys Arg Glu Ile 450 455 <210> 3 <211> 35 <212> DNA <213> Artificial Sequence <220> <221> primer_bind <222> (1)..(35) <223> Forward primer <400> 3 ccggaattct aatgaccacc acatttctgc aaaac 35 <210> 4 <211> 37 <212> DNA <213> Artificial Sequence <220> <221> primer_bind <222> (1)..(37) <223> Reverse primer <400> 4 cccaagcttt tagatttctc tcttgtggga agaaacc 37 <210> 5 <211> 57 <212> DNA <213> Artificial Sequence <220> <221> primer_bind <222> (1)..(57) <223> Forward Oligonucleotide <400> 5 ccgggaagcc gaagtatctc agcttctcga gaagctgaga tcttcggctt ctttttg 57 <210> 6 <211> 57 <212> DNA <213> Artificial Sequence <220> <221> primer_bind <222> (1)..(57) <223> Reverse oligonucleotide <400> 6 aattcaaaaa gaagccgaag tatctcagct tctcgagaag ctgagatctt cggcttc 57 <210> 7 <211> twenty one <212> RNA <213> Artificial Sequence <220> <222> (1)..(21) <223> KRT15-1 positive sense siRNA <400> 7 agccgaagua ucucagcuuu u 21 <210> 8 <211> twenty one <212> RNA <213> Artificial Sequence <220> <222> (1)..(21) <223> KRT15-1 antisense siRNA <400> 8 aagcugagau acuucggcuu c 21 <210> 9 <211> twenty one <212> RNA <213> Artificial Sequence <220> <222> (1)..(21) <223> KRT15-2 positive sense siRNA <400> 9 cugccuucag agagcugaau u 21 <210> 10 <211> twenty one <212> RNA <213> Artificial Sequence <220> <222> (1)..(21) <223> KRT15-2 antisense siRNA <400> 10 uucagcucuc ugaaggcagg g 21

Claims

1. A shRNA for knocking down KRT15, ​​characterized in that The forward oligonucleotide of the shRNA is shown in SEQ ID NO:5, and the reverse oligonucleotide of the shRNA is shown in SEQ ID NO:

6.

2. A siRNA for knocking down KRT15, ​​characterized in that: The sense strand of the siRNA is shown as SEQ ID NO: 7, and the antisense strand is shown as SEQ ID NO: 8, or the sense strand of the siRNA is shown as SEQ ID NO: 9, and the antisense strand is shown as SEQ ID NO:

10.

3. Use of the shRNA according to claim 1 or the siRNA according to claim 2 in preparing a drug for treating esophageal cancer.